BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Bio-Path Holdings, Inc. (the “Company”) held its 2019 annual meeting (the “2019 Annual Meeting”) of stockholders of the Company on December 19, 2019 in The Woodlands, Texas. At the 2019 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (the “2017 Plan”) to increase the number of shares of the Company’s common stock that may be issued under the 2017 Plan by 600,000 shares for a total of 660,000 shares. A description of the 2017 Plan is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 1, 2019 under the heading “Proposal Two: Approval Of An Amendment To The Company’s 2017 Stock Incentive Plan To Increase The Number Of Shares Of Common Stock That May Be Issued Under The Plan By 600,000 Shares For A Total Of 660,000 Shares,” which description is incorporated herein by reference. This summary is qualified in its entirety by the full text of the Amendment, which is filed as Exhibit 10.1 hereto, and the 2017 Plan, which is filed as Exhibit 10.2 hereto.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2019 Annual Meeting, the Company’s stockholders: (i) elected the five persons listed below under Proposal 1 to serve as directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified; (ii) approved the Amendment to the 2017 Plan; (iii) approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers; (iv) approved, on a non-binding advisory basis, the frequency of “every three years” for the stockholders’ non-binding advisory vote on the compensation of the Company’s named executive officers; and (v) ratified and approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2019. The following describes the results of the voting at the 2019 Annual Meeting:
| 10.1 | First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan |
| 10.2 | Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 27, 2017). |
BIO-PATH HOLDINGS INC Exhibit
EX-10.1 2 tm1926828d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO BIO-PATH HOLDINGS,…
To view the full exhibit click here
About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.